DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Monday.com - 1 FactSet - 1 Matt Gline - 1 Roche - 1 Bernstein - 1 GitLab - 1 Henry Schein - 1 — CNBC's Michelle Fox - 1
Top related locs:
Top related orgs:
Tyson - 1 Boeing - 1 Emirates Airlines - 1 Sciences - 1 Roivant Sciences - 1 Revenue - 1 HP Inc - 1 Citi - 1

Search resuls for: "Matt Gline"


2 mentions found


☆ Stocks making the biggest moves premarket: Tyson Foods, Boeing, Monday.com and more
  + stars: | 2023-11-13 | by ( Sarah Min | ) www.cnbc.com   time to read: +2 min
Check out the companies making headlines before the bell: Monday.com — Shares of the project management company jumped 10% after Monday.com reported a strong quarter and issued a rosy forecast. Monday.com reported third-quarter earnings and revenue of 64 cents per share on revenue of $189.2 million. Tyson Foods — The food products company fell 3.3% in premarket trading after Tyson's fiscal fourth-quarter revenue came in weaker than expected. Boeing — Shares rose 3.25% after Emirates Airlines announced the purchase of 95 Boeing aircraft for a total of $52 billion. TripAdvisor — Shares of the online booking company added 2.3% after Bernstein upgraded TripAdvisor to outperform from market perform.
Persons: Monday.com, FactSet, Matt Gline, Roche, Bernstein, GitLab, Henry Schein, — CNBC's Michelle Fox, Alex Harring, Jesse Pound, Pia Singh Organizations: Tyson, Boeing, Emirates Airlines, Sciences, Roivant Sciences, Revenue, HP Inc, Citi
☆ Roivant, Pfizer team up on inflammatory disease drug
  + stars: | 2022-12-01 | by ( Bhanvi Satija Khushi Mandowara | Bhanvi Satija | Khushi Mandowara | ) www.reuters.com   time to read: +2 min
Dec 1 (Reuters) - Biotech firm Roivant Sciences (ROIV.O) on Thursday launched a company with Pfizer Inc (PFE.N) focused on an experimental bowel disease treatment, as the drugmakers seek to tap into a multibillion dollar market. The drug, RVT-3101, was originally developed by Pfizer, which will hold a 25% stake in the new business, with Roivant holding the majority interest. SVB Securities analyst David Risinger says the deal shows how Pfizer is prioritizing research spending for its oral ulcerative colitis drug, etrasimod, which holds a near-term blockbuster opportunity. RVT-3101 could represent a nearly $15 billion commercial opportunity in the United States for Roivant as a treatment for both ulcerative colitis and Crohn’s disease, said Risinger. Pfizer has also licensed its inflammatory autoimmune disease drug brepocitinib to Roivant in exchange for a 25% stake in another jointly held company called Priovant.
0 next >>
Total: 2